Cybin Inc. Common Stock
HELP
Rangering i aksjer
#11559
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Aksjekurs
$10.30
Sist synkronisert: 2026-08-11
Markedsverdi
$638.32M
Endring (1 dag)
2.88%
Endring (1 år)
9,119.52%
Land
CA
Handel Cybin Inc. Common Stock (HELP)
Kategori
Healthcare
Aksjeprishistorikk for Cybin Inc. Common Stock (HELP)
Høyeste sluttskurs: $0.12 den 2023-10-01
Laveste sluttskurs: $0.40 den 2021-06-01
Laveste sluttskurs: $0.40 den 2021-06-01
Aksjeprishistorikk for Cybin Inc. Common Stock fra 2021 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2023 | 81.70% |
| 2022 | -76.32% |
| 2021 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
